Sara Napoli

This study identifies DDX21 as a key effector of ETS1/FLI1 in ABC-DLBCL, linking it to cell cycle, immune evasion, and snoRNA processing, with potential therapeutic implications.

This study identifies IL-16 production as a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas, showing that targeting the IL-16/CD9 axis restores drug sensitivity.

The paper shows ibrutinib increases CD19 expression in B-cell lymphoma models, improving the effectiveness of CD19-CAR T cells.

This study identifies multiple resistance mechanisms to ETS-targeting agents in DLBCL and suggests combination therapies with BCL2, MCL1, and XPO1 inhibitors.

This study identifies PLK1 inhibition as a strategy to enhance BTK blockade in MZL by overcoming resistance through transcriptomic and mechanistic analysis.

EasyCircR detects and reconstructs circRNA-miRNA-mRNA regulatory networks through post-transcriptional analysis and visualization.

This paper identifies ADARreg, an elncRNA that modulates BCR signaling and immune evasion in lymphoma by altering RNA stability, localization, and editing, providing a potential therapeutic target.

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.